[go: up one dir, main page]

HUP0001528A2 - Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére - Google Patents

Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére

Info

Publication number
HUP0001528A2
HUP0001528A2 HU0001528A HUP0001528A HUP0001528A2 HU P0001528 A2 HUP0001528 A2 HU P0001528A2 HU 0001528 A HU0001528 A HU 0001528A HU P0001528 A HUP0001528 A HU P0001528A HU P0001528 A2 HUP0001528 A2 HU P0001528A2
Authority
HU
Hungary
Prior art keywords
sulfonylurea
glitazone
diabetes
combinations
therapy
Prior art date
Application number
HU0001528A
Other languages
English (en)
Inventor
Randall W. Whitcomb
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HUP0001528A2 publication Critical patent/HUP0001528A2/hu
Publication of HUP0001528A3 publication Critical patent/HUP0001528A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A jelen találmány diabéteszellenes szulfonil-karbamid vegyületek ésglitazon vegyületek kombinációjára, és ilyen kombinációk diabéteszkezelésére történő alkalmazására vonatkozik. A II típusú diabéteszt azinzulinrezisztencia mellett főként a glükóz stimulusra adott csökkenthasnyálmirigy válasz jelzi. Az inzulinrezisztencia javítása - egyglitazon vegyület adagolásával - nagy előnnyel jár, amikor egyfolyamatban levő, inzulinfelszabadulás stimulálására alkalmas (példáulszulfonilkarbamid), terápiával kapcsolják össze. A glitazon ésszulfonilkarbamid kombinációs terápia biztonságosnak és jóltorelálhatónak mutatkozik és a glikémiás kontrollban szignifikáns ésszinergetikus javulást eredményezhet. A szulfonil-karbamid maximálisdózisaival kezelt betegeket nem szabad glitazon monoterápiáraátállítani. A monoterápiát, amennyiben javallott, csak a szulfonil-karbamid dózis lefelé titrálásával szabad elérni. A vizsgálateredményeinek alkalmazása nem korlátozódhat olyan betegekre, akikesetében a maximális dózisú szulfonil-karbamid terápia nem hatásos,hanem a szulfonil-karbamid kisebb dózisaival kezelt betegekre iskiterjeszthető. Ó
HU0001528A 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergic combinations for diabetes HUP0001528A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (2)

Publication Number Publication Date
HUP0001528A2 true HUP0001528A2 (hu) 2000-11-28
HUP0001528A3 HUP0001528A3 (en) 2000-12-28

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001528A HUP0001528A3 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergic combinations for diabetes

Country Status (29)

Country Link
US (2) US5859037A (hu)
EP (1) EP0957923A1 (hu)
JP (1) JP2001512478A (hu)
KR (1) KR20000071179A (hu)
CN (1) CN1244801A (hu)
AR (1) AR011829A1 (hu)
AU (1) AU741215B2 (hu)
BG (1) BG103671A (hu)
BR (1) BR9714505A (hu)
CA (1) CA2272478A1 (hu)
CZ (1) CZ289299A3 (hu)
EA (1) EA199900725A1 (hu)
EE (1) EE9900345A (hu)
GT (1) GT199800037A (hu)
HN (1) HN1997000167A (hu)
HU (1) HUP0001528A3 (hu)
IL (1) IL130027A (hu)
IS (1) IS5058A (hu)
NO (1) NO993982D0 (hu)
NZ (1) NZ336002A (hu)
PA (1) PA8447401A1 (hu)
PE (1) PE74399A1 (hu)
PL (1) PL335166A1 (hu)
SK (1) SK111899A3 (hu)
SV (1) SV1998000010A (hu)
TR (1) TR199902033T2 (hu)
UY (1) UY24893A1 (hu)
WO (1) WO1998036755A1 (hu)
ZA (1) ZA981343B (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
SK286028B6 (sk) * 1997-06-18 2008-01-07 Smithkline Beecham Plc Farmaceutický prostriedok a jeho použitie
DE122007000054I1 (de) * 1997-06-18 2007-12-13 Smithkline Beecham Plc Behandlung der Diabetes mit Thiazolidindione und metformin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
AU4956699A (en) 1998-06-19 2000-01-05 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
BR9917005A (pt) * 1998-12-24 2002-04-02 Metabasis Therapeutics Inc Combinação de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
EP1100895B1 (en) * 1999-03-15 2007-06-13 University of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
DE60103203T2 (de) 2000-04-13 2005-05-04 Pfizer Products Inc., Groton Synergistische Wirkung von Glyburide und Milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP1539144B1 (en) 2002-09-20 2014-12-24 Andrx Labs Llc Multistage formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
PL1677792T3 (pl) 2003-10-31 2016-05-31 Takeda Pharmaceuticals Co Stały preparat zawierający pioglitazon, glimepiryd i ester polioksyetylenosorbitanu z kwasem tłuszczowym
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd COMBINED MEDICATION FOR THE TREATMENT OF DIABETES
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
EP1937716A2 (en) * 2005-09-08 2008-07-02 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
MY149306A (en) 2005-12-22 2013-08-30 Takeda Pharmaceutical Solid preparation containing an insulin sensitizer
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
PT2068909E (pt) 2007-03-30 2012-07-04 Ambrx Inc Polipéptidos fgf-21 modificados e suas utilizações
PL2868315T3 (pl) 2007-12-04 2018-06-29 Biogen Chesapeake Llc Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
RU2765463C2 (ru) 2008-12-04 2022-01-31 Чунси ЮЙ Композиции интенсивного проникновения и их применение
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
BR112012011237A2 (pt) * 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
WO2011146981A1 (en) 2010-05-24 2011-12-01 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
AU2012207357B2 (en) 2011-01-19 2016-07-28 Fractyl Health, Inc. Devices and methods for the treatment of tissue
US9737559B2 (en) 2011-11-23 2017-08-22 Ozstar Therapeutics Pty Ltd Synergistic anti-diabetic compositions
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
EP4066764A1 (en) 2012-02-27 2022-10-05 Fractyl Health, Inc. Heat ablation systems and devices for the treatment of tissue
AU2013249043B2 (en) 2012-04-19 2017-04-27 Fractyl Health, Inc. Tissue expansion devices, system and methods
EP3714826A1 (en) 2012-07-30 2020-09-30 Fractyl Laboratories, Inc. Electrical energy ablation systems and devices for the treatment of tissue
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
KR102284469B1 (ko) 2013-11-22 2021-08-02 프랙틸 헬쓰, 인코포레이티드 위장관에 치료 제한부를 생성하기 위한 시스템, 장치 및 방법
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
EP3169260B1 (en) 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
EP3412302B1 (en) 2014-10-24 2021-05-12 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
US20230139684A1 (en) * 2019-11-22 2023-05-04 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
JP2001512478A (ja) 2001-08-21
EP0957923A1 (en) 1999-11-24
US5859037A (en) 1999-01-12
BR9714505A (pt) 2000-03-21
US5972973A (en) 1999-10-26
EA199900725A1 (ru) 2000-04-24
KR20000071179A (ko) 2000-11-25
NO993982L (no) 1999-08-18
UY24893A1 (es) 1998-07-10
HUP0001528A3 (en) 2000-12-28
AU741215B2 (en) 2001-11-29
BG103671A (en) 2000-04-28
ZA981343B (en) 1998-11-16
PE74399A1 (es) 1999-08-20
NZ336002A (en) 2002-03-28
AR011829A1 (es) 2000-09-13
CA2272478A1 (en) 1998-08-27
IL130027A0 (en) 2000-02-29
IL130027A (en) 2005-09-25
EE9900345A (et) 2000-02-15
SV1998000010A (es) 1999-02-02
PA8447401A1 (es) 2001-12-14
TR199902033T2 (xx) 2000-02-21
CN1244801A (zh) 2000-02-16
WO1998036755A1 (en) 1998-08-27
GT199800037A (es) 1999-08-12
PL335166A1 (en) 2000-04-10
AU5590898A (en) 1998-09-09
HN1997000167A (es) 1999-02-09
IS5058A (is) 1999-05-27
SK111899A3 (en) 2000-09-12
CZ289299A3 (cs) 1999-11-17
NO993982D0 (no) 1999-08-18

Similar Documents

Publication Publication Date Title
HUP0001528A2 (hu) Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére
Chalmers et al. Physiological significance of the sweat response to adrenaline in man
ATE344023T1 (de) Transdermales therapeutisches pflaster mit capsaicin und seinen analogen
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
BR0015295A (pt) Formulação e método antidiabético
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
MY155270A (en) Use of glp-1 or analogs in treatment of stroke
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
HK143395A (en) Site-directed mutagenesis modified glycoprotein hormones and methods of use
BRPI0502691A (pt) composição farmacêutica para o controle da glicose no sangue de pacientes com diabetes tipo 2
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
NO20000007D0 (no) Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet
AU6102801A (en) Method of preventing or treating diabetes
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
Antic et al. Decreased lymphocyte 5'-nucleotidase activity in NIDDM patients treated with gliclazide
Ignatov et al. The analgetic activity of antidepressants and their influence on the pain-relieving effect of acupuncture
Walling Adolescent diabetes and use of insulin-like growth-factor-1.
ATE328604T1 (de) Verwendung von wachstumshormon in niederen dosen
姚尊华 et al. OBSERVATION ON 52 CASES OF PARALYSIS OF COMMON PERONEAL NERVE TREATED BY ACUPUNCTURE AND PLUM-BLOSSOM NEEDLING
Soboleva Evaluation of factors providing oxygen of the tissues in miners with vibration disease treated by hyperbaric oxygenation.